AVO features in CNY Business Journal

RNS Number : 5095H

Advanced Oncotherapy PLC

20 May 2014

 



ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

AVO features in CNY Business Journal

Advanced Oncotherapy (AIM: AVO), the developer of innovative medical technology for cancer treatment, announces that a significant article has been published in the Central New York Business Journal (CNYBJ).  The article outlines the history and strategy of the partnership that AVO has created with State University of New York Upstate Medical University (SUNY Upstate) to build the first proprietary Linac Image Guided Hadron Therapy (LIGHT) system in North America, a proton beam for treating cancer. 

AVO and the SUNY Upstate signed a letter of intent to establish a relationship, which includes building a three-room, proton-treatment facility; a specialist training centre; and a research program in collaboration with CERN (European Organisation for Nuclear Research). In addition to collaborating with SUNY Update, AVO plans to set up a comprehensive customer operation in Syracuse to manufacture, assemble, test, market, and distribute this new generation of proton therapy machines for sale in North America and South America.

CNYBJ, which is published in Syracuse NY, USA, is a well-established journal which was founded in 1986 by the Publisher Emeritus Norm Poltenson. The print version is very influential in the area and circulates weekly to 25,000 executives in a 125 km, radius around Syracuse. The web-site usage has doubled since last year with the morning and afternoon electronic news roundups going out to separate audiences of about 9,000 each. The average reader is around 50 with an average annual household income of $215,000 and a net worth 1.5 million. 76% have some form of tertiary education and are classified as company owner/partner/top manager.

The article was written by Norm Poltenson, a founder of CNYBJ, and is a result of a series of interviews with all the key personnel in the Company.

The full article can be viewed at http://www.advancedoncotherapy.com/News.aspx 

Michael Sinclair, CEO of Advanced Oncotherapy commented: "This article details the whole process that led to us to partner with SUNY Upstate Medical Centre for the first commercial LIGHT system in North America. Following the successful funding we can now move ahead with our plans with them to build a LIGHT proton facility in Syracuse near the heart of their medical campus, that serves a catchment area of almost 2 million people. We felt that it was important to notify UK investors in AVO of this article, which they might otherwise not see."

For further information contact:

Advanced Oncotherapy Plc	www.avoplc.com
Michael Sinclair (CEO)	Tel: [phone]
Westhouse Securities	Tel: [phone]
Antonio Bossi (Nomad & Joint Broker)
David Coaten
Peterhouse Corporate Finance	Tel: [phone]
Jon Levinson (Joint Broker)
Lucy Williams
Walbrook PR
Mike Wort (Financial PR & IR)	Tel: [phone] or [e-mail]
Lianne Cawthorne

About Advanced Oncotherapy Plc 

Vision:

To advance patients' clinical treatments and improve their everyday lives by harnessing innovative science and focusing it to develop the most effective and affordable cancer treatments.

Mission:

To facilitate the wider use of radiation with protons for treating all forms of cancerous tumours by commercialising novel technologies inspired by CERN and the Large Hadron Collider

Key messages:

AVO's team based at CERN near Geneva focuses on the development of a proprietary proton system called Linac Image Guided Hadron Technology (LIGHT). This LIGHT system accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

AVO is a provider of proton radiotherapy that harnesses the best in modern technology.  As a result, the Company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology which is proven to bring better health outcomes and lower treatment related side effects.

AVO continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships the Company will remain the prime provider of innovative and cost-effective equipment for proton radiation. This will allow healthcare suppliers to access more cost effective and more efficient ways to treat the increasing number of cancer patients who expect lower short term and long term side effects of their cancer care. 

For more information, please visit http://www.avoplc.com

 

END

 

 

NRABUGDUUXBBGSC